Search Results 151-160 of 18355 for alopecia

1. Pediatric dermatology - Overview - Mayo Clinic

   Atopic dermatitis (eczema). Birthmarks, such as hemangioma and port-wine stain. Connective tissue disorders of the skin. Contact dermatitis. Dermatoses of ...

2. Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer - Mayo Clinic

   All acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1; Patients who are ...

3. A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Recovery from non-hematologic toxic effects of prior therapy to grade ≤ 1 (except alopecia) by NCI CTCAE Version 4.03. Adequate bone marrow (BM), renal ...

4. Carboplatin and Gemcitabine Hydrochloride With or Without VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

   ... alopecia. Patients with treatment related effects, such as peripheral neuropathy, that are grade 1 or less are eligible. Prior exposure to gemcitabine ...

5. Allergy skin tests - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Diffuse capillary malformation with overgrowth, Vulvar skin disorder, Blue rubber bleb nevus syndrome, Vascular anomaly, Vascular ...

6. A Study Comparing Gemcitabine with or without AZD 1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

   ... alopecia or peripheral neuropathy can also be included; Palliative radiation to < 10% of bone marrow is permissible if completed within one week of ...

7. Study of Canakinumab in Patients With Myelofibrosis - Mayo Clinic

   excluding alopecia. - Women of childbearing potential (WCBP) must have a negative urine or serum pregnancy test within 28 days of starting the study drug ...

8. ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies - Mayo Clinic

   Note: Subjects with Grade ≤ 2 neuropathy or Grade ≤ 2 alopecia are an exception to the latter criterion and may qualify for the study. Women who are ...

9. An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy - Mayo Clinic

   For Part A only: Participants who did not recover from all clinically significant toxicities (excluding alopecia and hematologic toxicities) of any previous ...

10. Study of Pembrolizumab Combined with Decitabine and Pralatrexate in Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma - Mayo Clinic

    The following are exceptions to this criterion: subjects with vitiligo or alopecia; subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable ...